ORGO Organogenesis Holdings Inc.
Healthcare$2.66+0.00%ClosedMarket Cap: $342.3M
As of 2026-05-26
Valuation
P/E (TTM)
7.85
PEG
0.00
P/B
0.89
P/S
0.67
EV/EBITDA
7.29
DCF Value
$2.54
FCF Yield
5.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
70.4%
Operating Margin
2.1%
Net Margin
-0.1%
ROE
-0.1%
ROA
-0.1%
ROIC
-0.2%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $37.2M | -2.5% | $-65.0M | $-56.2M | $— | — |
| Q4 null | $225.1M | 77.8% | $65.2M | $43.7M | $— | — |
| FY null | $563.0M | 75.6% | $55.9M | $37.0M | $— | — |
| Q3 null | $150.5M | 75.9% | $21.6M | $21.6M | $— | — |
| Q2 null | $100.8M | 72.6% | $-10.8M | $-9.4M | $— | — |
| Q1 null | $86.7M | 72.6% | $-20.2M | $-18.8M | $— | — |
| Q4 null | $126.7M | 75.5% | $10.2M | $7.7M | $— | — |
| FY null | $482.0M | 76.0% | $-1.3M | $861.0K | $— | — |
| Q3 null | $115.2M | 76.7% | $6.2M | $12.3M | $— | — |
| Q2 null | $130.2M | 77.6% | $-13.9M | $-17.0M | $— | — |
| Q1 null | $110.0M | 73.9% | $-3.9M | $-2.1M | $— | — |
| Q4 2023 | $99.7M | 72.1% | $-1.3M | $-568.0K | $-0.00 | — |